Guardant Health Inc

For the period ended Dec 31, 2024. Filed Feb 20, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 20, 2025

GH$158.79+5.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations

(in thousands, except per share data)

	Year Ended December 31,
	2024	2023	2022
Revenue:
Precision oncology testing	$687,936	$514,249	$392,049
Development services and other	51,080	49,699	57,489
Total revenue	739,016	563,948	449,538
Costs and operating expenses:
Cost of precision oncology testing	260,581	205,528	148,199
Cost of development services and other	29,218	21,524	8,126
Research and development expense	347,753	367,194	373,807
Sales and marketing expense	364,935	295,227	299,828
General and administrative expense	180,123	155,800	163,956
Other operating expense	—	83,400	—
Total costs and operating expenses	1,182,610	1,128,673	993,916
Loss from operations	(443,594)	(564,725)	(544,378)
Interest income	53,691	35,365	6,069
Interest expense	(2,581)	(2,578)	(2,577)
Other income (expense), net	(42,605)	53,174	(12,778)
Fair value adjustments of noncontrolling interest liability	—	—	(99,785)
Loss before provision for income taxes	(435,089)	(478,764)	(653,449)
Provision for income taxes	1,284	685	1,139
Net loss	$(436,373)	$(479,449)	$(654,588)
Net loss per share, basic and diluted	$(3.56)	$(4.28)	$(6.41)
Weighted-average shares used in computing net loss per share, basic and diluted	122,745	111,988	102,178

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.